Washington University's WU-CART-007 targets aggressive T-cell leukemias — a space where China has no approved therapy. The two countries are playing largely different games in CAR-T right now.
On March 26, 2026, the FDA granted Breakthrough Therapy designation to WU-CART-007 (soficabtagene goleucel), an experimental CAR-T cell therapy developed by Washington University School of Medicine researchers and licensed to their startup Wugen. The designation covers treatment of adults and adolescents with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) — aggressive blood cancers with notoriously poor outcomes.
The Phase 1 clinical data behind the designation is striking. Among 11 evaluable patients, the overall response rate came in at 91%, with 72.7% achieving complete remission. Six patients who went on to receive stem cell transplants remained in remission at the 6-12 month follow-up mark. For context: patients with these cancers who don't respond to initial treatment have a median survival of roughly six months, and fewer than 7% survive five years.
Most CAR-T therapies on the market today are autologous: doctors take a patient's own T cells, reprogram them in a lab, then give them back. That takes three to four weeks. WU-CART-007 is different — it's allogeneic, meaning donor cells go into any matched patient, with no waiting. For a cancer that can kill in months, that speed matters enormously.
Dr. John F. DiPersio, the WashU oncologist who led development, put it plainly: "Patients often deteriorate while waiting for personalized cell therapies. An off-the-shelf option addresses that critical gap."
China approved its first CAR-T therapy in June 2021: Yescarta (axicabtagene ciloleucel), delivered through the Fosun Kite joint venture. Unlike WU-CART-007, Yescarta targets CD19, a protein found on the surface of B cells — not T cells. Its approved indications include diffuse large B-cell lymphoma, follicular lymphoma, and primary mediastinal large B-cell lymphoma.
Since then, China has greenlit at least three more CAR-T products, including idecabtagene vicleucel variants and agentesleucel for different hematologic malignancies. Several domestic developers — Legend Biotech, JW Therapeutics, and Caribou Biosciences — have active pipelines targeting both blood cancers and solid tumors. In early 2026, Chinese researchers also reported a 57.1% response rate in a solid-tumor CAR-T trial, a figure that drew global attention.
China's biggest edge in CAR-T right now is price. US list prices sit above $400,000 per treatment. Chinese hospitals charge a fraction of that — typically one-third to one-fifth of US rates. Shanghai Ruijin Hospital, Peking Union Medical College Hospital, and several private oncology centers have built dedicated CAR-T programs that actively serve international patients.
One notable case: a South African patient with relapsed/refractory multiple myeloma traveled specifically to Shanghai for CAR-T treatment at a private clinic, achieving stable remission and discharge within weeks of arrival. Stories like this reflect a broader trend — the city reported an 8% year-over-year increase in foreign patients at public hospitals in 2025, with oncology as a leading specialty.
| Factor | United States (WU-CART-007) | China (Approved CAR-T Therapies) |
|---|---|---|
| Target Cancer Type | T-cell leukemias and lymphomas (T-ALL, T-LL) | Primarily B-cell lymphomas (DLBCL, FL, PMBCL) |
| Therapy Approach | Allogeneic ("off-the-shelf" from donor cells) | Autologous (patient's own cells) — approved therapies |
| Response Rate (Phase 1) | 91% overall response, 72.7% complete remission | Varies; Yescarta showed ~70% objective response in registrational trials |
| FDA/EUA Approval Status | Breakthrough Therapy designation (not yet approved); Phase 2 ongoing | Multiple products approved since 2021 (NMPA) |
| Estimated Cost per Treatment | TBD upon approval; likely $400,000–$500,000+ (US market) | ~$80,000–$150,000 (significantly lower than US) |
| Treatment Wait Time | Ready-made product; minimal wait | 3–4 weeks (autologous manufacturing) |
| International Patient Access | Limited initially; clinical trial enrollment primarily US-based | Established programs in Shanghai, Beijing; medical tourism infrastructure in place |
| Solid Tumor Capability | Not yet; currently hematologic malignancies only | Early-stage solid tumor trials showing ~57% response rate (2026) |
WU-CART-007 fills a genuine gap. T-cell cancer patients who relapse have had almost nothing beyond chemotherapy and stem cell transplant — and the outcomes were grim. A 91% response rate in Phase 1 is genuinely striking.
That said, WU-CART-007 is years from approval. When it arrives in the US, expect a price tag pushing $500,000 before you even count hospital and admin costs.
China, meanwhile, has been building out its CAR-T program quietly but seriously. Multiple approved products, a pipeline that's moving fast, costs that are a fraction of US prices, and hospitals that already handle foreign patients. The gap: none of China's approved CAR-T therapies work on T-cell cancers. For those specific leukemia and lymphoma types, US clinical trials are likely still the only route — assuming patients can get in and afford it.
For B-cell lymphoma and myeloma patients, though, China is worth a serious look. Proven technology, oncologists who have done hundreds of cases, and bills that won't destroy families financially.
Our coordination team can help you understand which therapies are available, connect you with the right specialists, and navigate the practicalities of receiving treatment as an international patient.
Get a Free Consultation